THE ASSESSMENT OF REVERSIBILITY - WHAT DRUGS

被引：0

|

作者：

DAHL, R ^{[1
]}

LOFDAHL, CG ^{[1
]}

机构：

[1] GOTHENBURG UNIV,DEPT PULM MED,S-41124 GOTHENBURG,SWEDEN

来源：

EUROPEAN RESPIRATORY JOURNAL | 1990年 / 3卷 / 09期

关键词：

D O I：

暂无

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

引用

收藏

页码：1087 / 1088

页数：2

相关论文

共 50 条

[1] THE ASSESSMENT OF REVERSIBILITY - WHAT PHYSIOLOGICAL TESTS
DEMEDTS, M
[J]. EUROPEAN RESPIRATORY JOURNAL, 1990, 3 (09) : 1084 - 1087
[2] Assessment of biotechnology drugs: what are the issues?
McKenna, SP
Whalley, D
[J]. HEALTH POLICY, 1999, 49 (03) : 195 - 197
[3] Assessment of biotechnology drugs: what are the issues?
van Rijkom, J
Leufkens, H
Crommelin, D
Rutten, F
Broekmans, A
[J]. HEALTH POLICY, 1999, 47 (03) : 255 - 274
[4] TACHYPHYLAXIS TO DECAMETHONIUM AND REVERSIBILITY OF BLOCK BY ANTICHOLINESTERASE DRUGS
FREUND, FG
[J]. ANESTHESIOLOGY, 1969, 30 (01) : 7 - &
[5] ASSESSMENT OF ANTIDIABETIC DRUGS IN FRANCE: WHAT IS THE BASIS FOR A REIMBURSEMENT RECOMMENDATION?
Dumet, A. F.
Chavade, D.
Busin, C.
Fernandez, J.
Galbraith, M.
Grande, M.
d'Andon, A.
[J]. VALUE IN HEALTH, 2017, 20 (09) : A482 - A482
[6] ORPHAN DRUGS: WHAT IS THE IMPACT OF SPECIAL PROVISIONS IN VALUE ASSESSMENT?
Epstein, M.
Michel, S.
[J]. VALUE IN HEALTH, 2022, 25 (07) : S508 - S508
[7] REVERSIBILITY OF LEFT-VENTRICULAR HYPERTROPHY BY ANTIHYPERTENSIVE DRUGS
FAGARD, RH
[J]. NETHERLANDS JOURNAL OF MEDICINE, 1995, 47 (04): : 173 - 179
[8] THE ASSESSMENT OF REVERSIBILITY - SHORT-TERM
WETTENGEL, R
[J]. EUROPEAN RESPIRATORY JOURNAL, 1990, 3 (09) : 1088 - 1089
[9] CRITERIA FOR ASSESSMENT OF REVERSIBILITY IN AIRWAYS OBSTRUCTION
不详
[J]. CHEST, 1974, 65 (05) : 552 - 553
[10] WHAT DRUGS, AT WHAT PRICES
NAIR, A
[J]. ECONOMIC AND POLITICAL WEEKLY, 1986, 21 (24) : 1037 - 1037

← 1 2 3 4 5 →